Share
Jim Anthony
Parexel, a leading global clinical research organization (CRO), has appointed Jim Anthony to the expanded role of Chief Commercial Officer (CCO) and President, Parexel Biotech.
The move strengthens Parexel’s customer-focused strategy and enhances its ability to drive growth and value across both biotech and pharmaceutical sectors.
Mr. Anthony has led Parexel Biotech since its launch in 2019 and most recently served as President and Global Head. In his expanded role, he will oversee global customer strategy and partnerships across biotech and pharma, leveraging Parexel’s integrated Clinical and Consulting solutions and therapeutic expertise spanning Phase I-IV development to accelerate the delivery of life-changing therapies.
As part of long-term succession planning, Conal Burgess, President and Global Head of Enterprise Partnerships, will transition from Parexel on December 31, 2025, after a distinguished 30-year career. Mr. Burgess played a pivotal role in establishing and growing strategic partnerships with large pharmaceutical companies, creating a strong foundation for Parexel’s continued success.
Mr. Anthony brings over 25 years of experience in pharmaceutical development and clinical research services. Since joining Parexel in 2010 as Vice President, North America Business Development, he has held senior leadership roles including Corporate Vice President, Enterprise Account Leader, and Executive Vice President and Global Head, Parexel Biotech, before being appointed President and Global Head in 2023.
His expanded responsibilities reflect Parexel’s commitment to advancing customer collaboration and accelerating clinical development globally.
